《大行》交銀國際升康方生物(09926.HK)目標價至183元 評級「買入」
交銀國際發表研究報告指,考慮到康方生物(09926.HK)HARMONi研究樣本數量更大,預計最終分析總生存期(OS)達到統計學顯着的可能性較大。該行表示,將產品海外經 PoS 調整高峯預測上調至165億美元。
該行指,公司上半年商業銷售收入按年增長49%至14億元人民幣,主要得益於卡度尼利和依沃西兩款核心雙抗產品於年初正式納入醫保目錄,同時PCSK9 和 IL12/IL23 啓動商業化。公司銷售團隊人數超1,200名,並繼續完善腫瘤和特藥事業部分線。
該行調整集團在2025年至2027年財務預測,同時將其目標價由140港元上調至183港元,其評級爲「買入」。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.